TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer

被引:122
作者
Erber, R
Conradt, C
Homann, N
Enders, C
Finckh, M
Dietz, A
Weidauer, H
Bosch, FX
机构
[1] Heidelberg Univ, Hals Nasen Ohren Klin, Mol Biol Lab, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Inst Med Biometrie, D-69120 Heidelberg, Germany
[3] Klinikum Buch, Hals Nasen Ohren Klin, D-13122 Berlin, Germany
关键词
TP53; mutation types; clinical course; head and neck cancer;
D O I
10.1038/sj.onc.1201690
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent studies have suggested that different mutation types within the core domain of the tumour suppressor protein p53, i.e. DNA contact mutations and structural mutations, confer different biological properties, We have analysed in 86 head and neck squamous cell carcinomas (HNSCC), whether these p53 mutation types have a differential clinical impact, Thirty-seven missense mutations were identified, Thirteen of these (36%) were DNA contact mutations, occurring in the L3 loop, in the H2 loop sheet helix motif, in the S10 beta strand and in Zinc binding residues, Microsatellite marker analysis revealed a selective association between these mutations and the loss of wild-type alleles (100% LOH vs 50% LOH in tumours with structural mutations; P=0.0034, Fisher's exact, 2-tailed), In comparison to structural mutations or to the absence of mutations in the core domain, DNA contact mutations were associated with higher tumour stages (84.6% vs 62%), a higher incidence of lymph node metastasis (91.7% vs 56%; P=0.014, Fisher's exact, 2-tailed), a shortened recurrence-free survival (8.1 months vs 23.7 months, P=0.047, log rank test) and overall survival (11 months vs 29.2 months; P=0.003, log rank test), The latter was also the case when only stage IV tumours were analysed (P=0.0055, log rank test), These data indicate that in HNSCC, TP53 DNA contact mutations confer a strong selection pressure to eliminate mild-type alleles, and that they result in an accelerated tumour progression and reduced therapeutic responsiveness.
引用
收藏
页码:1671 / 1679
页数:9
相关论文
共 27 条
  • [1] Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
    Aas, T
    Borresen, AL
    Geisler, S
    SmithSorensen, B
    Johnsen, H
    Varhaug, JE
    Akslen, LA
    Lonning, PE
    [J]. NATURE MEDICINE, 1996, 2 (07) : 811 - 814
  • [2] AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217
  • [3] PROGNOSTIC-SIGNIFICANCE OF TP53 ALTERATIONS IN BREAST-CARCINOMA
    ANDERSEN, TI
    HOLM, R
    NESLAND, JM
    HEIMDAL, KR
    OTTESTAD, L
    BORRESEN, AL
    [J]. BRITISH JOURNAL OF CANCER, 1993, 68 (03) : 540 - 548
  • [4] COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY
    BERGH, J
    NORBERG, T
    SJOGREN, S
    LINDGREN, A
    HOLMBERG, L
    [J]. NATURE MEDICINE, 1995, 1 (10) : 1029 - 1034
  • [5] BOYLE JO, 1993, CANCER RES, V53, P4477
  • [6] BRACHMAN DG, 1992, CANCER RES, V52, P4832
  • [7] CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS
    CHO, YJ
    GORINA, S
    JEFFREY, PD
    PAVLETICH, NP
    [J]. SCIENCE, 1994, 265 (5170) : 346 - 355
  • [8] GAIN OF FUNCTION MUTATIONS IN P53
    DITTMER, D
    PATI, S
    ZAMBETTI, G
    CHU, S
    TERESKY, AK
    MOORE, M
    FINLAY, C
    LEVINE, AJ
    [J]. NATURE GENETICS, 1993, 4 (01) : 42 - 46
  • [9] FORRESTER K, 1995, ONCOGENE, V10, P2103
  • [10] Friedlander P, 1996, MOL CELL BIOL, V16, P4961